Improvement of systemic sclerosis by death receptor agonist

摘要

The present disclosure relates to methods and compositions for treating and / or preventing autoimmune fibrosis, such as systemic sclerosis (SSc; scleroderma). The method includes administering an effective amount of a death receptor agonist to a subject in need thereof. Suitable death receptor agonists include tumor necrosis factor (TNF) -related apoptosis-inducing ligand (TRAIL), agonistic death receptor antibodies, and variants, analogs or derivatives thereof. Administration of a death receptor agonist blocks fibroblasts or profibrotic cell activation and / or reduces or depletes myofibroblasts, thereby reducing or preventing systemic sclerosis.